Tessera Therapeutics is at the forefront of genetic medicine with its innovative Gene Writing™ technology, which allows for precise modifications to the human genome. This platform enables the writing of therapeutic messages directly into the genome, addressing the root causes of diseases. The technology is capable of making both small and large alterations, providing a versatile approach to genome engineering. Tessera's Gene Writing™ aims to create potentially curative therapies for significant unmet medical needs, including genetic disorders like alpha-1 antitrypsin deficiency (AATD) and sickle cell disease (SCD).

In addition to its Gene Writing™ capabilities, Tessera is developing a proprietary lipid nanoparticle (LNP) delivery system designed for targeted, non-viral delivery of RNA to specific tissues. This delivery technology enhances the efficiency of genomic alterations, as demonstrated in preclinical studies where high rewriting efficiencies were achieved in both non-human primates and humanized mice. The combination of Gene Writing™ and advanced delivery methods positions Tessera Therapeutics to pioneer transformative genetic medicines that not only correct single-gene disorders but also have the potential to modify inherited risk factors for various diseases, including cancer and autoimmune conditions.

United States

Tessera Therapeutics is pioneering Gene Writing™—a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source.

Tessera Therapeutics

Company Details